These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 27598218)

  • 21. S100A9 and EGFR gene signatures predict disease progression in muscle invasive bladder cancer patients after chemotherapy.
    Kim WT; Kim J; Yan C; Jeong P; Choi SY; Lee OJ; Chae YB; Yun SJ; Lee SC; Kim WJ
    Ann Oncol; 2014 May; 25(5):974-9. PubMed ID: 24631944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer.
    Ivanova T; Zouridis H; Wu Y; Cheng LL; Tan IB; Gopalakrishnan V; Ooi CH; Lee J; Qin L; Wu J; Lee M; Rha SY; Huang D; Liem N; Yeoh KG; Yong WP; Teh BT; Tan P
    Gut; 2013 Jan; 62(1):22-33. PubMed ID: 22535375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
    Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
    Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
    Lu YT; Plets M; Morrison G; Cunha AT; Cen SY; Rhie SK; Siegmund KD; Daneshmand S; Quinn DI; Meeks JJ; Lerner SP; Petrylak DP; McConkey D; Flaig TW; Thompson IM; Goldkorn A
    Eur Urol Oncol; 2023 Oct; 6(5):516-524. PubMed ID: 37087309
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular biomarkers to predict response to neoadjuvant chemotherapy for bladder cancer.
    Buttigliero C; Tucci M; Vignani F; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2017 Mar; 54():1-9. PubMed ID: 28135623
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development.
    Balar AV; Milowsky MI
    Urol Clin North Am; 2015 May; 42(2):217-24, viii-ix. PubMed ID: 25882563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression and regulation of tumor suppressor gene maspin in human bladder cancer.
    Sugimoto S; Maass N; Takimoto Y; Sato K; Minei S; Zhang M; Hoshikawa Y; Jünemann KP; Jonat W; Nagasaki K
    Cancer Lett; 2004 Jan; 203(2):209-15. PubMed ID: 14732229
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer.
    Liu D; Abbosh P; Keliher D; Reardon B; Miao D; Mouw K; Weiner-Taylor A; Wankowicz S; Han G; Teo MY; Cipolla C; Kim J; Iyer G; Al-Ahmadie H; Dulaimi E; Chen DYT; Alpaugh RK; Hoffman-Censits J; Garraway LA; Getz G; Carter SL; Bellmunt J; Plimack ER; Rosenberg JE; Van Allen EM
    Nat Commun; 2017 Dec; 8(1):2193. PubMed ID: 29259186
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone Demethylase KDM7A Regulates Androgen Receptor Activity, and Its Chemical Inhibitor TC-E 5002 Overcomes Cisplatin-Resistance in Bladder Cancer Cells.
    Lee KH; Kim BC; Jeong SH; Jeong CW; Ku JH; Kim HH; Kwak C
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32781788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic and toxicity considerations in the use of neoadjuvant chemotherapy for bladder cancer.
    Narayan V; Vaughn D
    Expert Opin Drug Metab Toxicol; 2015 May; 11(5):731-42. PubMed ID: 25604887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Standard or accelerated methotrexate, vinblastine, doxorubicin and cisplatin as neoadjuvant chemotherapy for locally advanced urothelial bladder cancer: Does dose intensity matter?
    Pouessel D; Chevret S; Rolland F; Gravis G; Geoffrois L; Roubaud G; Terrisse S; Boyle H; Chevreau C; Dauba J; Moriceau G; Alexandre I; Deplanque G; Chapelle A; Vauleon E; Colau A; Audenet F; Grellety T; Culine S
    Eur J Cancer; 2016 Feb; 54():69-74. PubMed ID: 26724422
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.
    Blick C; Hall P; Pwint T; Al-Terkait F; Crew J; Powles T; Macaulay V; Munro N; Douglas D; Kilbey N; Protheroe A; Chester JD
    Cancer; 2012 Aug; 118(16):3920-7. PubMed ID: 22614698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA Methylation of miR-7 is a Mechanism Involved in Platinum Response through
    Vera O; Jimenez J; Pernia O; Rodriguez-Antolin C; Rodriguez C; Sanchez Cabo F; Soto J; Rosas R; Lopez-Magallon S; Esteban Rodriguez I; Dopazo A; Rojo F; Belda C; Alvarez R; Valentin J; Benitez J; Perona R; De Castro J; Ibanez de Caceres I
    Theranostics; 2017; 7(17):4118-4134. PubMed ID: 29158814
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
    Xiang Y; Ma N; Wang D; Zhang Y; Zhou J; Wu G; Zhao R; Huang H; Wang X; Qiao Y; Li F; Han D; Wang L; Zhang G; Gao X
    Oncogene; 2014 Jan; 33(3):378-86. PubMed ID: 23318422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rewiring of cisplatin-resistant bladder cancer cells through epigenetic regulation of genes involved in amino acid metabolism.
    Yeon A; You S; Kim M; Gupta A; Park MH; Weisenberger DJ; Liang G; Kim J
    Theranostics; 2018; 8(16):4520-4534. PubMed ID: 30214636
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24).
    Varol N; Konac E; Onen IH; Gurocak S; Alp E; Yilmaz A; Menevse S; Sozen S
    DNA Cell Biol; 2014 Jul; 33(7):408-17. PubMed ID: 24665856
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Upregulated expression of BCL2, MCM7, and CCNE1 indicate cisplatin-resistance in the set of two human bladder cancer cell lines: T24 cisplatin sensitive and T24R2 cisplatin resistant bladder cancer cell lines.
    Kim SH; Ho JN; Jin H; Lee SC; Lee SE; Hong SK; Lee JW; Lee ES; Byun SS
    Investig Clin Urol; 2016 Jan; 57(1):63-72. PubMed ID: 26966728
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel mechanism for acquired cisplatin-resistance: suppressed translation of death-associated protein kinase mRNA is insensitive to 5-aza-2'-deoxycitidine and trichostatin in cisplatin-resistant cervical squamous cancer cells.
    Bai T; Tanaka T; Yukawa K; Umesaki N
    Int J Oncol; 2006 Feb; 28(2):497-508. PubMed ID: 16391806
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.
    Choi W; Porten S; Kim S; Willis D; Plimack ER; Hoffman-Censits J; Roth B; Cheng T; Tran M; Lee IL; Melquist J; Bondaruk J; Majewski T; Zhang S; Pretzsch S; Baggerly K; Siefker-Radtke A; Czerniak B; Dinney CP; McConkey DJ
    Cancer Cell; 2014 Feb; 25(2):152-65. PubMed ID: 24525232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 5-azacytidine reverses drug resistance in bladder cancer cells.
    Ramachandran K; Gordian E; Singal R
    Anticancer Res; 2011 Nov; 31(11):3757-66. PubMed ID: 22110197
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.